OTC Markets OTCPK - Delayed Quote USD

(LAEKF)

7.30

0.00

(0.00%)

At close: January 2 at 10:25:12 AM EST

Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA

LOS ANGELES, March 04, 2025--Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors.

Business Wire 2 months ago

LAEKF
0.00%
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024

Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The presentation will feature preclinical characterization of LAE118, a novel allosteric pan-mutant selective PI3Kα inhibitor.

PR Newswire 4 months ago

LAEKF
0.00%

Performance Overview

Return	LAEKF	MSCI WORLD (^990100-USD-STRD)
YTD	--	+0.41%
1-Year	--	--
3-Year	--	+33.73%